Carbamazepine 10,11-epoxide in children

Area of Science:

• Pharmacology
• Clinical Chemistry
• Pediatric Medicine

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug in children.
• Monitoring CBZ and its active metabolite, carbamazepine-10,11-epoxide (CBZ-E), is crucial for therapeutic drug management.
• Non-invasive methods for drug monitoring are desirable in pediatric populations.

Purpose of the Study:

• To investigate the correlation between carbamazepine (CBZ) and its epoxide metabolite (CBZ-E) concentrations in plasma and saliva.
• To assess the utility of saliva as a non-invasive matrix for therapeutic drug monitoring of CBZ in children.
• To evaluate the pharmacokinetic profile and contribution of CBZ-E to the overall anticonvulsant effect in pediatric patients.

Main Methods:

• Simultaneous collection of plasma and mixed saliva samples from 15 children (aged 1-13 years) treated with carbamazepine.
• Hourly saliva sampling from six children over dose intervals to analyze CBZ and CBZ-E concentrations.
• Statistical analysis to determine the correlation between plasma and saliva concentrations and to assess drug fluctuations.

Main Results:

• Significant correlations were observed between saliva and plasma concentrations for both CBZ (r=0.91) and CBZ-E (r=0.91).
• The steady-state CBZ-E/CBZ concentration ratio in saliva was consistently around 0.40 +/- 0.21.
• Percentage fluctuations in combined CBZ + CBZ-E levels were less pronounced than those of CBZ-E alone, suggesting a stabilizing effect.

Conclusions:

• Saliva is a reliable and non-invasive matrix for monitoring carbamazepine (CBZ) and its active metabolite CBZ-epoxide (CBZ-E) in children.
• The consistent CBZ-E/CBZ ratio in saliva supports its use in assessing drug exposure and potential therapeutic effects.
• CBZ-E contributes significantly to the overall anticonvulsant activity, potentially up to 30% in children on CBZ monotherapy.